<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Exp Mol Med</journal-id>
        <journal-id journal-id-type="iso-abbrev">Exp. Mol. Med</journal-id>
        <journal-id journal-id-type="pmc-domain-id">872</journal-id>
        <journal-id journal-id-type="pmc-domain">emm</journal-id>
        <journal-title-group>
          <journal-title>Experimental &amp; Molecular Medicine</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1226-3613</issn>
        <issn pub-type="epub">2092-6413</issn>
        <publisher>
          <publisher-name>Korean Society for Biochemistry and Molecular Biology</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC5903820</article-id>
        <article-id pub-id-type="pmcid-ver">PMC5903820.1</article-id>
        <article-id pub-id-type="pmcaid">5903820</article-id>
        <article-id pub-id-type="pmcaiid">5903820</article-id>
        <article-id pub-id-type="pmid">29422544</article-id>
        <article-id pub-id-type="doi">10.1038/emm.2017.265</article-id>
        <article-id pub-id-type="pii">emm2017265</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Original Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Mutational signatures and chromosome alteration profiles of squamous cell carcinomas of the vulva</article-title>
          <alt-title alt-title-type="running">Mutations and CNAs in vulvar cancer</alt-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Han</surname>
              <given-names initials="MR">Mi-Ryung</given-names>
            </name>
            <xref ref-type="aff" rid="aff1">1</xref>
            <xref ref-type="aff" rid="aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Shin</surname>
              <given-names initials="S">Sun</given-names>
            </name>
            <xref ref-type="aff" rid="aff1">1</xref>
            <xref ref-type="aff" rid="aff2">2</xref>
            <xref ref-type="aff" rid="aff3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Park</surname>
              <given-names initials="HC">Hyeon-Chun</given-names>
            </name>
            <xref ref-type="aff" rid="aff1">1</xref>
            <xref ref-type="aff" rid="aff2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kim</surname>
              <given-names initials="MS">Min Sung</given-names>
            </name>
            <xref ref-type="aff" rid="aff4">4</xref>
            <xref ref-type="aff" rid="aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lee</surname>
              <given-names initials="SH">Sung Hak</given-names>
            </name>
            <xref ref-type="aff" rid="aff6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jung</surname>
              <given-names initials="SH">Seung Hyun</given-names>
            </name>
            <xref ref-type="aff" rid="aff1">1</xref>
            <xref ref-type="aff" rid="aff2">2</xref>
            <xref ref-type="aff" rid="aff5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Song</surname>
              <given-names initials="SY">Sang Yong</given-names>
            </name>
            <xref ref-type="aff" rid="aff7">7</xref>
            <xref ref-type="corresp" rid="caf1">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lee</surname>
              <given-names initials="SH">Sug Hyung</given-names>
            </name>
            <xref ref-type="aff" rid="aff4">4</xref>
            <xref ref-type="aff" rid="aff5">5</xref>
            <xref ref-type="corresp" rid="caf2">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chung</surname>
              <given-names initials="YJ">Yeun-Jun</given-names>
            </name>
            <xref ref-type="aff" rid="aff1">1</xref>
            <xref ref-type="aff" rid="aff2">2</xref>
            <xref ref-type="aff" rid="aff3">3</xref>
            <xref ref-type="corresp" rid="caf3">*</xref>
          </contrib>
          <aff id="aff1"><label>1</label><institution>Department of Integrated Research Center for Genome Polymorphism, The Catholic University of Korea</institution>, Seoul, <country>Korea</country></aff>
          <aff id="aff2"><label>2</label><institution>Precision Medicine Research Center, The Catholic University of Korea</institution>, Seoul, <country>Korea</country></aff>
          <aff id="aff3"><label>3</label><institution>Department of Microbiology, The Catholic University of Korea</institution>, Seoul, <country>Korea</country></aff>
          <aff id="aff4"><label>4</label><institution>Department of Pathology, The Catholic University of Korea</institution>, Seoul, <country>Korea</country></aff>
          <aff id="aff5"><label>5</label><institution>Cancer Evolution Research Center, The Catholic University of Korea</institution>, Seoul, <country>Korea</country></aff>
          <aff id="aff6"><label>6</label><institution>Department of Hospital Pathology, The Catholic University of Korea</institution>, Seoul, <country>Korea</country></aff>
          <aff id="aff7"><label>7</label><institution>Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution>, Seoul, <country>Korea</country></aff>
        </contrib-group>
        <author-notes>
          <corresp id="caf1"><label>*</label><institution>Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine</institution> 81 Ilwon-ro, Kangnam-gu, Seoul 06351, <country>Korea</country>. E-mail: <email>yodasong@hanmail.net</email></corresp>
          <corresp id="caf2"><label>*</label><institution>Precision Medicine Research Center, The Catholic University of Korea, College of Medicine</institution>, 222 Banpo-daero, Socho-gu, Seoul 06591, <country>Korea</country>. E-mail: <email>suhulee@catholic.ac.kr</email></corresp>
          <corresp id="caf3"><label>*</label><institution>Department of Pathology, The Catholic University of Korea</institution>, Seoul, <country>Korea</country>. E-mail: <email>yejun@catholic.ac.kr</email></corresp>
        </author-notes>
        <pub-date pub-type="ppub">
          <month>02</month>
          <year>2018</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>09</day>
          <month>02</month>
          <year>2018</year>
        </pub-date>
        <volume>50</volume>
        <issue>2</issue>
        <issue-id pub-id-type="pmc-issue-id">310662</issue-id>
        <fpage>e442</fpage>
        <lpage/>
        <history>
          <date date-type="received">
            <day>31</day>
            <month>05</month>
            <year>2017</year>
          </date>
          <date date-type="rev-recd">
            <day>30</day>
            <month>08</month>
            <year>2017</year>
          </date>
          <date date-type="accepted">
            <day>04</day>
            <month>09</month>
            <year>2017</year>
          </date>
        </history>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>02</month>
              <year>2018</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>19</day>
              <month>04</month>
              <year>2018</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2018-06-08 20:29:35.993">
              <day>08</day>
              <month>06</month>
              <year>2018</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>Copyright © 2018 The Author(s)</copyright-statement>
          <copyright-year>2018</copyright-year>
          <copyright-holder>The Author(s)</copyright-holder>
          <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
            <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p>
          </license>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="emm2017265a.pdf"/>
        <abstract>
          <p>Vulvar squamous cell carcinoma (SCC) consists of two different etiologic categories: human papilloma virus (HPV)-associated (HPV (+)) and HPV-non-associated (HPV (−)). There have been no genome-wide studies on the genetic alterations of vulvar SCCs or on the differences between HPV (+) and HPV (−) vulvar SCCs. In this study, we performed whole-exome sequencing and copy number profiling of 6 HPV (+) and 9 HPV (−) vulvar SCCs and found known mutations (<italic toggle="yes">TP53</italic>, <italic toggle="yes">CDKN2A</italic> and <italic toggle="yes">HRAS</italic>) and copy number alterations (CNAs) (7p and 8q gains and 2q loss) in HPV (−) SCCs. In HPV (+), we found novel mutations in <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">BRCA2</italic> and <italic toggle="yes">FBXW7</italic> that had not been reported in vulvar SCCs. HPV (−) SCCs exhibited more mutational loads (numbers of nonsilent mutations and driver mutations) than HPV (+) SCCs, but the CNA loads and mutation signatures between HPV (+) and HPV (−) SCCs did not differ. Of note, 40% and 40% of the 15 vulvar SCCs harbored <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">FAT1</italic> alterations, respectively. In addition, we found that the SCCs harbored kataegis (a localized hypermutation) in 2 HPV (+) SCCs and copy-neutral losses of heterozygosity in 4 (one HPV (+) and 3 HPV (−)) SCCs. Our data indicate that HPV (+) and HPV (−) vulvar SCCs may have different mutation and CNA profiles but that there are genomic features common to SCCs. Our data provide useful information for both HPV (+) and HPV (−) vulvar SCCs and may aid in the development of clinical treatment strategies.</p>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
    <body>
      <sec>
        <title>Introduction</title>
        <p>Vulvar cancer is a malignant invasive lesion occurring in the vaginal opening, the labia majora (the most common site), the labia minora and the clitoris. Vulvar cancer accounts for 0.6% of all cancer diagnoses and 5% of gynecologic cancers.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref></sup> Vulvar cancer is typically a squamous cell carcinoma (SCC) that is also common in other gynecologic organs, including the cervix and vagina.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref></sup> Whereas almost all cervical SCCs occur with the background of human papillomavirus (HPV) infection,<sup><xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref></sup> vulvar SCCs consist of those associated with HPV as well as others independent of HPV infection.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref></sup> Both HPV (+) and HPV (−) vulvar SCCs are preceded by vulvar intraepithelial neoplasia (VIN).<sup><xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib6">6</xref></sup> These two types of vulvar SCCs along with their precursors exhibit different epidemiological, pathological, clinical and molecular features.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib6">6</xref></sup> Approximately one-third of all vulvar SCC patients suffer from recurrence, for which therapeutic options are limited.<sup><xref ref-type="bibr" rid="bib7">7</xref></sup></p>
        <p>SCCs developed in female genital tracts share common features, including HPV infection and the progression of squamous intraepithelial neoplasia to invasive SCCs.<sup><xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref></sup> Like cervical intraepithelial neoplasia, VINs progress to SCCs but the progression rates are lower than those of cervical lesions,<sup><xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib6">6</xref></sup> indicating that the pathogenesis of cervical and vulvar SCCs may differ in part.</p>
        <p>With the improvement of next-generation sequencing (NGS) technology, comprehensive molecular profiles of many cancers have been studied using NGS,<sup><xref ref-type="bibr" rid="bib8">8</xref></sup> which allows for the investigation of thousands of variants within a given tumor sample.<sup><xref ref-type="bibr" rid="bib9">9</xref>, <xref ref-type="bibr" rid="bib10">10</xref>, <xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib12">12</xref></sup> Using a targeted sequencing approach for 14 genes, a recent study identified that most HPV-negative (−) vulvar SCCs (83%) contained one or more somatic mutations in <italic toggle="yes">TP53</italic>, <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">HRAS</italic>, <italic toggle="yes">KRAS</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">PPP2R1A</italic> and <italic toggle="yes">PTEN</italic>, with <italic toggle="yes">TP53</italic> being the most commonly mutated gene.<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> In contrast, HPV-positive (+) vulvar SCCs harbored a <italic toggle="yes">TP53</italic> mutation in 17% of cases but the remaining 83% were silent without any driver mutations.<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> Their study strongly suggests not only that HPV-dependent and HPV-independent vulvar SCCs may have different mutation profiles but also there could be hidden mutations not discovered by the targeted approach only for the 14 genes. Other studies using conventional gene-to-gene analyses have shown similar mutation data in vulvar SCCs.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib14">14</xref>, <xref ref-type="bibr" rid="bib15">15</xref></sup> Thus far, a number of studies have reported the mutational profiles of SCC in many organs (non-genital: head/neck, esophagus and skin; genital: uterine cervix and penis) using high-throughput genome profiling technologies.<sup><xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib16">16</xref>, <xref ref-type="bibr" rid="bib17">17</xref>, <xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib19">19</xref></sup> However, to date, the genomic data of vulvar SCCs at the whole-genome or whole-exome level is absent. Thus, it is necessary to examine the mutational profiles of vulvar SCCs in addition to the well-known gene mutations, including <italic toggle="yes">TP53</italic>. In this study, we analyzed the genomes of 15 vulvar SCCs using NGS-based whole-exome sequencing (WES) to identify the mutational profiles of vulvar SCCs.</p>
      </sec>
      <sec>
        <title>Materials and methods</title>
        <sec>
          <title>Vulvar cancer tissues</title>
          <p>Vulvar SCC tissues resected by surgery were obtained from 15 Korean patients. Tissues from one patient were frozen (VSCC2) and those from the other 14 patients were formalin-fixed paraffin-embedded (FFPE). This study was approved by the Institutional Review Board (IRB) at The Catholic University of Korea, College of Medicine. Clinicopathologic characteristics of the 15 vulvar SCC patients are summarized in <xref rid="tbl1" ref-type="table">Table 1</xref>. Both frozen and FFPE tissues were cut and examined under a microscope by two pathologists. Tumor and normal cells were selectively procured from hematoxylin-stained sections by microdissection. The purity of the tumor cells from the microdissection was approximately 70%. HPV (+) tumors were determined using real-time polymerase chain reaction (PCR) for HPV obtained from a commercial company for molecular diagnosis (Seegene, Inc., Seoul, Korea).</p>
        </sec>
        <sec>
          <title>WES and somatic mutations</title>
          <p>WES was performed on the genomic DNA obtained from tumor and matched normal tissues using the Agilent SureSelect Human All Exome V4 Kit (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer’s instructions. WES data were processed as previously described.<sup><xref ref-type="bibr" rid="bib20">20</xref></sup> Briefly, the paired-end sequencing raw data (FASTQ format) were aligned to the human reference genome (hg19) using Burrows–Wheeler aligner software (BWA, v0.7.15).<sup><xref ref-type="bibr" rid="bib21">21</xref></sup> The Genome Analysis toolkit (GATK, v3.6),<sup><xref ref-type="bibr" rid="bib22">22</xref></sup> Picard (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://picard.sourceforge.net">http://picard.sourceforge.net</ext-link>; v2.7.1) and Samtools (v1.3.1)<sup><xref ref-type="bibr" rid="bib23">23</xref></sup> were used for the basic processing and management of marking duplicates, including local realignments and score recalibration. Somatic mutations were detected by comparing tumor and matched normal sequencing data using MuTect<sup><xref ref-type="bibr" rid="bib24">24</xref></sup> and SomaticIndelDetector<sup><xref ref-type="bibr" rid="bib22">22</xref></sup> for point mutations and indels, respectively. ANNOVAR (Annotate Variation) was used for the functional annotation of each variant in the coding regions.<sup><xref ref-type="bibr" rid="bib25">25</xref></sup> PolyPhen-2 was used to predict the impact of an amino-acid substitution on protein function and structure.<sup><xref ref-type="bibr" rid="bib26">26</xref></sup> We validated 21 mutations of 9 genes using either digital PCR or Sanger sequencing. Putative regions of kataegis were identified in samples where mutations had an average inter-mutation distance of no more than 10 kb.<sup><xref ref-type="bibr" rid="bib27">27</xref></sup></p>
        </sec>
        <sec>
          <title>Comprehensive analysis of mutational signatures</title>
          <p>Somatic mutation signatures were estimated using the SomaticSignatures R package,<sup><xref ref-type="bibr" rid="bib28">28</xref></sup> in which a mutation spectrum was decomposed with a non-negative matrix factorization (NMF) algorithm. Mutational signature analyses were rerun 20 times to confirm the results and an optimal number of signatures was chosen based on the maximum differentiation between the signatures. To compare the mutation signatures of the 15 vulvar SCCs with other cancer types, we first calculated the similarities between the mutational signatures using 30 known signatures recorded in the Catalogue of Somatic Mutations in Cancer (COSMIC) database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/cosmic/signatures">http://cancer.sanger.ac.uk/cosmic/signatures</ext-link>).<sup><xref ref-type="bibr" rid="bib29">29</xref></sup> Similarities between mutational signatures were calculated using a cosine correlation similarity ranging from 0 and 1, where one represented identical signatures and zero represented completely non-identical signatures. Next, we systematically analyzed the mutational signatures of SCCs using data from The Cancer Genome Atlas (TCGA)<sup><xref ref-type="bibr" rid="bib30">30</xref></sup> and a comprehensive literature review of NGS-based studies for SCCs.<sup><xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib16">16</xref>, <xref ref-type="bibr" rid="bib31">31</xref>, <xref ref-type="bibr" rid="bib32">32</xref>, <xref ref-type="bibr" rid="bib33">33</xref></sup> Data were composed of four types of SCCs from TCGA (CESC: cervical squamous cell carcinoma, ESCA: esophageal squamous cell carcinoma, HNSC: head and neck squamous cell carcinoma, LUSC: lung squamous cell carcinoma)<sup><xref ref-type="bibr" rid="bib30">30</xref></sup> and two SCCs from NGS-based studies (CSCC: skin cutaneous squamous cell carcinoma,<sup><xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib16">16</xref></sup> OSCC: oral squamous cell carcinoma<sup><xref ref-type="bibr" rid="bib31">31</xref>, <xref ref-type="bibr" rid="bib32">32</xref>, <xref ref-type="bibr" rid="bib33">33</xref></sup>).</p>
        </sec>
        <sec>
          <title>DNA copy number and loss of heterozygosity analyses</title>
          <p>Copy number alterations (CNAs) were defined for each of the 15 vulvar SCCs using the ngCGH module and RankSegmentation statistical algorithm in NEXUS software v7.5 (Biodiscovery, Inc., El Segundo, CA, USA).<sup><xref ref-type="bibr" rid="bib34">34</xref></sup> Loss of heterozygosity (LOH) events were inferred using Sequenza.<sup><xref ref-type="bibr" rid="bib35">35</xref></sup> Identified CNAs and LOH events were manually curated based on the depth ratio and B allele frequency.</p>
        </sec>
      </sec>
      <sec>
        <title>Results</title>
        <sec>
          <title>The catalog of somatic mutations</title>
          <p>A total of 15 vulvar SCC genomes (6 HPV (+) and 9 HPV (−)) and paired normal tissue genomes were analyzed in this study (<xref rid="tbl1" ref-type="table">Table 1</xref>). The coverage of the sequencing depth was a median of 141.8X (90.6–171.4X) for SCCs and 130.0X (60.6–180.7X) for paired normal tissues (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S1</xref>). A total of 2084 nonsilent (27–297/per tumor; median of 130) and 924 silent mutations were identified in the vulvar SCC genomes with a mean rate of 5.6 somatic mutations per megabase (<xref ref-type="fig" rid="fig1">Figure 1a and b</xref>, <xref ref-type="supplementary-material" rid="sup1">Supplementary Table S2</xref>). These rates are higher than those of CESC (3.0 per megabase), ESCA (2.8), HNSC (3.3) and OSCC (2.6), but lower than those of CSCC (12.5) and LUSC (7.4). In terms of the sequence characteristics of point mutations, the C&gt;T substitution was the most common type (31.0% 56.8% at CpG and 43.2% at non-CpG contexts) (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). The frequencies of somatic nonsilent mutations in HPV (−) SCCs (average of 175 per tumor) were significantly higher than those of HPV (+) SCCs (average of 84.8 per tumor) (<italic toggle="yes">P</italic>=0.03). The base substitutions were mainly C&gt;T or C&gt;G and did not differ between HPV (+) and HPV (−) SCCs. Comparison data between HPV (+) and HPV (−) SCCs are summarized in <xref rid="tbl2" ref-type="table">Table 2</xref>.</p>
        </sec>
        <sec>
          <title>Cancer-related genes</title>
          <p>Cancer-related genes were extracted from the Cancer Gene Census (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/census">http://cancer.sanger.ac.uk/census</ext-link>)<sup><xref ref-type="bibr" rid="bib36">36</xref></sup> and genes previously reported in vulvar SCCs.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib14">14</xref>, <xref ref-type="bibr" rid="bib15">15</xref></sup> We identified a total of 56 cancer-related genes that contained not only known vulvar SCC mutations (<italic toggle="yes">TP53</italic>, <italic toggle="yes">CDKN2A</italic>, <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">HRAS</italic>) but also previously unknown vulvar SCC mutations, including <italic toggle="yes">APC</italic>, <italic toggle="yes">FBXW7</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">RB1</italic> and <italic toggle="yes">FAT1</italic> (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). The putative driver mutations showed significantly higher mutation allele frequencies (mean MAFs; 0.19) than the other mutations (mean MAFs: 0.16, <italic toggle="yes">P</italic>=0.02). The PolyPhen-2 analysis<sup><xref ref-type="bibr" rid="bib26">26</xref></sup> revealed that the majority of the putative driver mutations (34 of 56, 61%) were predicted to have damaging effects on protein function (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S3</xref>).</p>
          <p>Recurrent nonsilent mutations (⩾2 cases) were found in 21 genes, including <italic toggle="yes">TP53</italic> (5 cases), <italic toggle="yes">APC</italic> (3 cases), <italic toggle="yes">KMT2C</italic> (3 cases) and <italic toggle="yes">PIK3CA</italic> (2 cases) (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). The number of driver mutations in HPV (−) SCCs (average of 10.6 per tumor) was significantly higher than that of HPV (+) SCCs (average of 2.8 per tumor) (<italic toggle="yes">P</italic>=0.0002). However, 4 of 6 HPV (+) SCCs still harbored one of the known driver gene mutations (<italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">BRCA2</italic> and <italic toggle="yes">FBXW7</italic>) (<xref rid="tbl2" ref-type="table">Table 2</xref>). There were more non-synonymous mutations in HPV (−) SCCs (average of 6.8 per tumor) than HPV (+) SCCs (average of 1.5 per tumor) and <italic toggle="yes">TP53</italic> was the most frequently mutated gene in the vulvar SCC genomes (<xref ref-type="fig" rid="fig2">Figure 2a</xref>).</p>
          <p>Six truncating mutations were identified in known tumor suppressor genes (TSGs) <italic toggle="yes">FAT1</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">CASP8</italic> and <italic toggle="yes">SMAD2</italic>. Of note, <italic toggle="yes">FAT1</italic> harbored nonsilent mutations in 3 SCCs: VSCC15 with a nonsense mutation (p.W4175X), VSCC13 with 2 different nonsense mutations (p.S3268X and p.Q1455X) and VSCC9 with a missense mutation (p.D3749N). Three of six truncating mutations were identified in the <italic toggle="yes">FAT1</italic> gene (p.W4175X, p.S3268X and p.Q1455X), which were located in known functional domains (cadherin domains and the intracytoplasmic domain) (<xref ref-type="fig" rid="fig2">Figure 2b</xref>).</p>
        </sec>
        <sec>
          <title>Mutation signatures</title>
          <p>We analyzed signatures of the somatic mutations detected in the vulvar SCCs using the NMF algorithm (<xref ref-type="fig" rid="fig3">Figure 3a and b</xref> and <xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S1</xref>) and found that C:G&gt;T:A transitions, which are frequently observed in mutations with oxidative DNA damage,<sup><xref ref-type="bibr" rid="bib37">37</xref></sup> were predominant in the vulvar SCCs. A decomposition of mutation spectra using the NMF algorithm revealed a pattern similar to signatures 1 and 2 in the COSMIC database (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). Signature 1 (S1) is related to endogenous mutational processes present in most cancers and signature 2 (S2) is characterized by over-activity of the APOBEC cytidine deaminases. Three SCCs (VSCC3, 7 and 9) and another 3 (VSCC4, 14 and 15) SCCs dominantly exhibited S1 and S2, respectively. In terms of HPV status, there was no clear difference in the mutational signatures between HPV (+) and HPV (−) SCCs. However, the C&gt;T transition, in the context of TpCpG trinucleotides, was more abundant in HPV (−) SCCs (average contribution of 0.17 per tumor) than in HPV (+) SCCs (average contribution of 0.14 per tumor). The contribution of the C&gt;T transition in the context of TpCpA trinucleotides was similar regardless of HPV status. When compared with other SCCs, cervical SCC showed the most similar mutation signature pattern (APOBEC family of cytidine deaminases) to the signature from the vulvar SCCs (<xref ref-type="supplementary-material" rid="sup1">Supplementary Figure S2</xref>).</p>
        </sec>
        <sec>
          <title>CNAs and LOH</title>
          <p>By analyzing the WES data, a total of 590 CNAs (334 gains and 256 losses) were identified in 13 vulvar SCCs (<xref ref-type="supplementary-material" rid="sup1">Supplementary Table S4</xref>). Two vulvar SCCs (VSCC9 and 15) were not included due to low qualities, which were measured by data noise level (quality score of 0.157 and 0.099 for VSCC9 and 15, respectively). No significant difference in the number or length of CNAs was observed between HPV (+) and HPV (−) genomes (<italic toggle="yes">P</italic>=0.53 and 0.75, respectively) (<xref rid="tbl2" ref-type="table">Table 2</xref>). In the HPV (+) SCCs, we found 15 recurrently altered CNA regions, where a gain on 3q25.33-q29 was the most recurrent event (83%) (<xref rid="tbl3" ref-type="table">Table 3</xref>). With regards to the HPV (−) SCCs, we found 18 recurrently altered CNA regions, where gains on 7p and 8q and a loss on 2q (all 57%) were the most recurrent CNAs (<xref rid="tbl3" ref-type="table">Table 3</xref>). The CNA profiles were largely compatible with previously identified CNAs in vulvar SCCs (<xref rid="tbl3" ref-type="table">Table 3</xref>).<sup><xref ref-type="bibr" rid="bib38">38</xref></sup> In earlier studies,<sup><xref ref-type="bibr" rid="bib38">38</xref></sup> an 8q gain (86%) and an 11q loss (29%) were the most common CNAs in HPV (−) vulvar SCCs. In the present study, 13q, 18p-q, 20p, and 20q gains were newly discovered in the HPV (+) SCCs (<xref rid="tbl3" ref-type="table">Table 3</xref>). In the HPV (−) SCCs, gains at 7p, 10q, 14q and 21p-q and losses at 2p and Xp-q were newly discovered (<xref rid="tbl3" ref-type="table">Table 3</xref>). Cancer-related genes such as <italic toggle="yes">FOXL2</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">TP63</italic>, <italic toggle="yes">SOX2</italic>, <italic toggle="yes">TERT</italic>, <italic toggle="yes">BCL2</italic>, <italic toggle="yes">SMAD2</italic> and <italic toggle="yes">GNAS</italic> in the regions of gains, as well as <italic toggle="yes">BIRC3</italic> in the region of loss, were detected in the SCCs (<xref rid="tbl3" ref-type="table">Table 3</xref>, <xref ref-type="fig" rid="fig4">Figure 4a and b</xref>).</p>
          <p>Importantly, 4 of 6 HPV (+) cases (VSCC1-4) showed copy gains at the <italic toggle="yes">PIK3CA</italic> locus (3q26.32). Two of them (VSCC1 and 4) harbored a hotspot missense mutation (p.E545K) (<xref ref-type="fig" rid="fig4">Figure 4c</xref>). The MAF of the missense mutation at the <italic toggle="yes">PIK3CA</italic> copy gain locus was 49% and the mean MAF in the copy-number neutral region was 24% in VSCC4. Similarly, in VSCC1, the MAF of the mutation in the <italic toggle="yes">PIK3CA</italic> copy gain locus was 21% and the mean MAF in the copy-number neutral region was 17%. Although further experimental validation is required, these data suggest that these two events may have occurred in the same allele. Two of 7 HPV (−) SCCs also exhibited copy gains at the <italic toggle="yes">PIK3CA</italic> locus.</p>
          <p>Next, we assessed the B-allele profiles of the 13 vulvar SCCs and identified 6 copy-neutral LOH events (2q33.1-q37.3, 3q11.2-q29, 7p22.3-p11.2, 7q22.1-q36.3, 9q22.2-q34.3 and 17p13.3-p11.2) in 4 (31%) cases (1 HPV (+) and 3 HPV (−)) where important cancer-related genes are located, including <italic toggle="yes">TP53</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">NOTCH1</italic>, <italic toggle="yes">CASP8</italic>, <italic toggle="yes">EGFR</italic>, <italic toggle="yes">BRAF</italic>, <italic toggle="yes">FOXL2</italic> and <italic toggle="yes">TP63</italic> (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p>
        </sec>
        <sec>
          <title>Localized hypermutation</title>
          <p>Two vulvar SCCs with HPV (+) had a recurrent region of kataegis (a focus of localized substitution hypermutations) at chromosome 16p12.3-q22.2 (chr16:19 566 736–72 137 834) (<xref ref-type="fig" rid="fig6">Figure 6</xref>). The mutations in kataegis are usually characterized by clusters of C&gt;T and/or C&gt;G in the text of TpC dinucleotides.<sup><xref ref-type="bibr" rid="bib39">39</xref></sup> In agreement, we observed that most mutations in the kataegis region involved Tp<underline>C</underline>pN mutations, with an inter-mutational distance of no more than 10 kb (<xref ref-type="fig" rid="fig6">Figure 6</xref>).<sup><xref ref-type="bibr" rid="bib27">27</xref></sup> Of note, the kataegis region in our study co-localized with the copy gain of the <italic toggle="yes">DHX38</italic> gene, which is involved in RNA splicing.</p>
        </sec>
      </sec>
      <sec>
        <title>Discussion</title>
        <p>Although the mutational landscape of cervical SCCs is already known,<sup><xref ref-type="bibr" rid="bib9">9</xref></sup> that of vulvar SCCs is unknown. The aim of this study was two-fold. First, we attempted to disclose somatic mutations and CNAs of vulvar SCCs genome-wide. Second, we attempted to disclose genomic differences between HPV (+) and HPV (−) vulvar SCCs. We found that the vulvar SCCs harbored not only known mutations in driver genes such as <italic toggle="yes">TP53</italic>, <italic toggle="yes">PIK3CA</italic> and <italic toggle="yes">HRAS</italic> but also novel mutations in cancer-related genes such as <italic toggle="yes">APC</italic>, <italic toggle="yes">FBXW7</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">RB1</italic> and <italic toggle="yes">FAT1</italic>. We also found mounting evidence that HPV (+) and HPV (−) SCCs may differ with respect to genetic alterations, some of which were previously unknown. For example, the <italic toggle="yes">TP53</italic> mutation was known as a sole driver mutation in HPV (+) vulvar SCCs<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> but other driver gene mutations (<italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">BRCA2</italic> and <italic toggle="yes">FBXW7</italic>) were detected in the HPV (+) SCCs in the present study.</p>
        <p>Most recurrent CNAs of HPV (+) SCCs in the present study were largely in agreement with those described in earlier studies, while those of HPV (−) were not, except for the gain on 8q.<sup><xref ref-type="bibr" rid="bib15">15</xref></sup> Of note, the gain on 3q was the most recurrent CNA in the HPV (+) vulvar SCCs, while the gains on 7p and 8q and the loss on 2q were the most recurrent in HPV (−) cases. Unlike somatic mutations that exhibited higher frequency in HPV (−) SCCs than in HPV (+) SCCs, the CNA frequencies between HPV (−) and HPV (+) vulvar SCC genomes did not differ. Together, our data suggest that a 3q gain where <italic toggle="yes">PIK3CA</italic> is located plays a role in vulvar SCC development irrespective of the HPV status and that the other CNAs could be related to HPV status. In the 5 SCCs (2 HPV (+) and 3 HPV (−)), we found a copy-neutral LOH, also called uniparental disomy (UPD), in which there are two copies of a chromosome from one parent and no copies from the other parent due to errors in meiosis I or meiosis II.<sup><xref ref-type="bibr" rid="bib40">40</xref></sup> The copy-neutral LOH may contribute to the development of tumors that are homozygous for preexisting mutations.<sup><xref ref-type="bibr" rid="bib41">41</xref></sup> The copy-neutral LOH areas in the vulvar SCCs identified in this study harbored tumor suppressor genes (<italic toggle="yes">TP53</italic> and <italic toggle="yes">CASP8</italic>) and an oncogene (<italic toggle="yes">PIK3CA</italic>). We are the first to report this copy-neutral LOH in vulvar SCCs; however, its distribution as well as its biological and clinical significance in vulvar SCCs remains to be clarified.</p>
        <p>Diverse endogenous and exogenous mutational processes leave distinct patterns of mutational signatures embedded within cancer genomes.<sup><xref ref-type="bibr" rid="bib42">42</xref></sup> Signature 1, initiated by the deamination of 5-methyl-cytosine, is found in the majority of human cancers<sup><xref ref-type="bibr" rid="bib43">43</xref></sup> and has a probable association with aging.<sup><xref ref-type="bibr" rid="bib42">42</xref></sup> Signature 2 is the second most common signature related to the APOBEC family of cytidine deaminases coupled with DNA replication and repair machineries.<sup><xref ref-type="bibr" rid="bib39">39</xref>, <xref ref-type="bibr" rid="bib44">44</xref></sup> The co-occurrence of these two signatures is found in SCCs from the cervix, head/neck and esophagus.<sup><xref ref-type="bibr" rid="bib42">42</xref></sup> The vulvar SCCs examined in this study had both signatures 1 and 2 without any other distinct signatures. These data suggest that vulvar SCCs may not harbor any other distinct mutational etiologies such as alcohol, tobacco and ultraviolet exposure besides HPV and aging.</p>
        <p>In two HPV (+) SCCs, we found recurrent kataegis, a process related to the activation of APOBEC enzymes, at 16p12.3-16q22.2 on the basis of substitution type and sequence context of cytosine mutations.<sup><xref ref-type="bibr" rid="bib39">39</xref>, <xref ref-type="bibr" rid="bib42">42</xref></sup> Currently, kataegis is not defined by a statistics-based analysis; therefore, although our observation of a kataegis-enriched mutation is in agreement with a previous report,<sup><xref ref-type="bibr" rid="bib39">39</xref></sup> a proper statistical method for such purposes should be developed. APOBEC activity is induced in HPV-infected cells and is highly associated with HPV (+) head/neck cancer.<sup><xref ref-type="bibr" rid="bib45">45</xref></sup> The 16q22.2 locus (with the kataegis) encompasses the <italic toggle="yes">DHX38</italic> gene that encodes an RNA helicase and is involved in RNA splicing.<sup><xref ref-type="bibr" rid="bib46">46</xref></sup> Whether the recurrent kataegis involving <italic toggle="yes">DHX38</italic> is specific for the tumorigenesis of vulvar SCCs remains to be studied in a larger cohort.</p>
        <p>The most common mutation identified in this study was the <italic toggle="yes">TP53</italic> mutation (5/15), consistent with previous studies.<sup><xref ref-type="bibr" rid="bib5">5</xref></sup> The <italic toggle="yes">TP53</italic> mutation in one case (VSCC8) was accompanied by a <italic toggle="yes">TP53</italic> copy loss, which would result in the complete inactivation of <italic toggle="yes">TP53</italic>. Six vulvar SCCs showed <italic toggle="yes">PIK3CA</italic> copy gains. Of them, 2 cases (VSCC1 and 4) harbored concurrent <italic toggle="yes">PIK3CA</italic> mutations, while the other 4 cases harbored only <italic toggle="yes">PIK3CA</italic> copy gains without any <italic toggle="yes">PIK3CA</italic> mutation. When combining the <italic toggle="yes">PIK3CA</italic> mutations with the copy gains, <italic toggle="yes">PIK3CA</italic> genetic alterations in vulvar SCCs reached 60%, suggesting that it may be the major genetic alteration in vulvar SCCs. Further experimental validation of the concurrent <italic toggle="yes">PIK3CA</italic> alteration and its biological roles will be required. Additionally, 3 HPV (−) SCCs harbored nonsense or missense mutations of the tumor suppressor gene <italic toggle="yes">FAT1</italic>, while the other 3 HPV (−) SCCs harbored <italic toggle="yes">FAT1</italic> copy losses. All of these events occurred in HPV (−) SCCs, suggesting that an alteration in <italic toggle="yes">FAT1</italic> would be an HPV (−) SCC-specific event, although the sample scale was not sufficient to conclude this hypothesis. Recurrent somatic mutations of <italic toggle="yes">FAT1</italic> have been reported in multiple human cancers, including head/neck SCC, cervical adenocarcinoma and glioblastoma;<sup><xref ref-type="bibr" rid="bib47">47</xref></sup> they reported truncating mutations (p.R146M, p.W543X and p.E314X) in the cadherin and cytoplasmic domains of the <italic toggle="yes">FAT1</italic> gene, the same locations as those reported in our study.<sup><xref ref-type="bibr" rid="bib47">47</xref></sup> In addition, <italic toggle="yes">FAT1</italic> inactivation by somatic mutations activates Wnt signaling and promotes tumorigenesis.<sup><xref ref-type="bibr" rid="bib47">47</xref></sup> HPV (−) head/neck SCCs harbor frequent <italic toggle="yes">FAT1</italic> mutations with loss of functions, which are significantly associated with better overall survival in HPV (−) patients but not in HPV (+) patients.<sup><xref ref-type="bibr" rid="bib48">48</xref></sup> Based on our data, the clinical significance of <italic toggle="yes">FAT1</italic> inactivation in vulvar SCCs should be further examined in future studies.</p>
        <p>Vulvar SCC has been divided into two different etiologic pathways (HPV-associated and HPV-non-associated). However, the genetic differences between these two have not been studied by genome-wide analyses. Based on the present study, the following conclusions were made: (i) the overall loads for somatic mutations (total mutations, nonsilent mutations and driver mutations) are higher in HPV (−) SCCs than in HPV (+) SCCs; (ii) the overall loads for CNAs (length and number) are not different; and (iii) the profiles of driver mutations and CNAs overlap but are not identical (<xref rid="tbl2" ref-type="table">Table 2</xref>). Several HPV-induced genes such as E6 and E7 act as oncogenes that promote tumor growth and malignant transformation, which could render HPV-infected cells less independent of additional somatic mutations for cancer development than HPV-uninfected cells.<sup><xref ref-type="bibr" rid="bib49">49</xref>, <xref ref-type="bibr" rid="bib50">50</xref></sup> Because there was no difference in the overall CNA loads, it can be hypothesized that HPV status may not have substantial effects during SCC development. The overlapping but different profiles of driver mutations and CNAs between HPV (+) and HPV (−) SCCs suggest that vulvar SCC development may require genetic alterations specific to either HPV-dependent or HPV-independent lesions in addition to common genetic alterations of HPV-dependent and HPV-independent SCCs.</p>
        <p>In summary, we report the global genomic alteration profiles of vulvar SCCs to provide a better understanding of both the HPV-dependent and HPV-independent pathogenesis of vulvar SCCs. The genomic features of vulvar SCCs identified in the current study aid in a better understanding of the etiology of vulvar SCCs.</p>
      </sec>
    </body>
    <back>
      <ack>
        <p>This study was supported by a grant from the National Research Foundation of Korea (2012R1A5A2047939) and by a grant from the Korea Healthcare Technology R&amp;D Project (HI14C3417 and HI13C2148).</p>
      </ack>
      <fn-group>
        <fn>
          <p><xref ref-type="supplementary-material" rid="sup1">Supplementary Information</xref> accompanies the paper on Experimental &amp; Molecular Medicine website (http://www.nature.com/emm)</p>
        </fn>
        <fn>
          <p>
            <bold>Publisher’s note</bold>
          </p>
          <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p>The authors declare no conflict of interest.</p>
        </fn>
      </fn-group>
      <ref-list>
        <ref id="bib1">
          <mixed-citation publication-type="journal">del Pino M, Rodriguez-Carunchio L, Ordi J. <article-title>Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma</article-title>. <source>Histopathology</source><year>2013</year>; <volume>62</volume>: <fpage>161</fpage>–175.<pub-id pub-id-type="pmid">23190170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/his.12034</pub-id></mixed-citation>
        </ref>
        <ref id="bib2">
          <mixed-citation publication-type="journal">Clancy AA, Spaans JN, Weberpals JI. <article-title>The forgotten woman’s cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy</article-title>. <source>Ann Oncol</source><year>2016</year>; <volume>27</volume>: <fpage>1696</fpage>–1705.<pub-id pub-id-type="pmid">27329249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdw242</pub-id></mixed-citation>
        </ref>
        <ref id="bib3">
          <mixed-citation publication-type="journal">zur Hausen H. <article-title>Papillomaviruses and cancer: from basic studies to clinical application</article-title>. <source>Nat Rev Cancer</source><year>2002</year>; <volume>2</volume>: <fpage>342</fpage>–350.<pub-id pub-id-type="pmid">12044010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc798</pub-id></mixed-citation>
        </ref>
        <ref id="bib4">
          <mixed-citation publication-type="journal">Woodman CBJ, Collins SI, Young LS. <article-title>The natural history of cervical HPV infection: unresolved issues</article-title>. <source>Nat Rev Cancer</source><year>2007</year>; <volume>7</volume>: <fpage>11</fpage>–22.<pub-id pub-id-type="pmid">17186016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc2050</pub-id></mixed-citation>
        </ref>
        <ref id="bib5">
          <mixed-citation publication-type="journal">Trietsch MD, Nooij LS, Gaarenstroom KN, van Poelgeest MI. <article-title>Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: a review of the current literature</article-title>. <source>Gynecol Oncol</source><year>2015</year>; <volume>136</volume>: <fpage>143</fpage>–157.<pub-id pub-id-type="pmid">25448458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2014.11.002</pub-id></mixed-citation>
        </ref>
        <ref id="bib6">
          <mixed-citation publication-type="journal">Hoang LN, Park KJ, Soslow RA, Murali R. <article-title>Squamous precursor lesions of the vulva: current classification and diagnostic challenges</article-title>. <source>Pathology</source><year>2016</year>; <volume>48</volume>: <fpage>291</fpage>–302.<pub-id pub-id-type="pmid">27113549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pathol.2016.02.015</pub-id><pub-id pub-id-type="pmcid">PMC5518939</pub-id></mixed-citation>
        </ref>
        <ref id="bib7">
          <mixed-citation publication-type="journal">Cormio G, Loizzi V, Carriero C, Cazzolla A, Putignano G, Selvaggi L. <article-title>Groin recurrence in carcinoma of the vulva: management and outcome</article-title>. <source>Eur J Cancer Care</source><year>2010</year>; <volume>19</volume>: <fpage>302</fpage>–307.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2354.2008.01011.x</pub-id><pub-id pub-id-type="pmid">19832900</pub-id></mixed-citation>
        </ref>
        <ref id="bib8">
          <mixed-citation publication-type="journal">Network TCGA. <article-title>Comprehensive molecular characterization of human colon and rectal cancer</article-title>. <source>Nature</source><year>2012</year>; <volume>487</volume>: <fpage>330</fpage>–337.<pub-id pub-id-type="pmid">22810696</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11252</pub-id><pub-id pub-id-type="pmcid">PMC3401966</pub-id></mixed-citation>
        </ref>
        <ref id="bib9">
          <mixed-citation publication-type="journal">Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ et al. <article-title>Landscape of genomic alterations in cervical carcinomas</article-title>. <source>Nature</source><year>2014</year>; <volume>506</volume>: <fpage>371</fpage>–375.<pub-id pub-id-type="pmid">24390348</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12881</pub-id><pub-id pub-id-type="pmcid">PMC4161954</pub-id></mixed-citation>
        </ref>
        <ref id="bib10">
          <mixed-citation publication-type="journal">Gao Y-B, Chen Z-L, Li J-G, Hu X-D, Shi X-J, Sun Z-M et al. <article-title>Genetic landscape of esophageal squamous cell carcinoma</article-title>. <source>Nat Genet</source><year>2014</year>; <volume>46</volume>: <fpage>1097</fpage>–1102.<pub-id pub-id-type="pmid">25151357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.3076</pub-id></mixed-citation>
        </ref>
        <ref id="bib11">
          <mixed-citation publication-type="journal">Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE et al. <article-title>Mutational landscape of aggressive cutaneous squamous cell carcinoma</article-title>. <source>Clin Cancer Res Off J Am Assoc Cancer Res</source><year>2014</year>; <volume>20</volume>: <fpage>6582</fpage>–6592.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-14-1768</pub-id><pub-id pub-id-type="pmcid">PMC4367811</pub-id><pub-id pub-id-type="pmid">25303977</pub-id></mixed-citation>
        </ref>
        <ref id="bib12">
          <mixed-citation publication-type="journal">Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y et al. <article-title>Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma</article-title>. <source>J Clin Invest</source><volume>126</volume>: <fpage>169</fpage>–180.<pub-id pub-id-type="pmid">26619122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI82066</pub-id><pub-id pub-id-type="pmcid">PMC4701554</pub-id></mixed-citation>
        </ref>
        <ref id="bib13">
          <mixed-citation publication-type="journal">Trietsch MD, Spaans VM, ter Haar NT, Osse EM, Peters AAW, Gaarenstroom KN et al. <article-title>CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma</article-title>. <source>Gynecol Oncol</source><year>2014</year>; <volume>135</volume>: <fpage>149</fpage>–155.<pub-id pub-id-type="pmid">25072932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ygyno.2014.07.094</pub-id></mixed-citation>
        </ref>
        <ref id="bib14">
          <mixed-citation publication-type="journal">Kunjoonju JP, Raitanen M, Grénman S, Tiwari N, Worsham MJ. <article-title>Identification of individual genes altered in squamous cell carcinoma of the vulva</article-title>. <source>Genes Chromosomes Cancer</source><year>2005</year>; <volume>44</volume>: <fpage>185</fpage>–193.<pub-id pub-id-type="pmid">16001430</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/gcc.20230</pub-id></mixed-citation>
        </ref>
        <ref id="bib15">
          <mixed-citation publication-type="journal">Zhang L, Wu J, Ling MT, Zhao L, Zhao K-N. <article-title>The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses</article-title>. <source>Mol Cancer</source><year>2015</year>; <volume>14</volume>: <fpage>87</fpage>.<pub-id pub-id-type="pmid">26022660</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-015-0361-x</pub-id><pub-id pub-id-type="pmcid">PMC4498560</pub-id></mixed-citation>
        </ref>
        <ref id="bib16">
          <mixed-citation publication-type="journal">Li YY, Hanna GJ, Laga AC, Haddad RI, Lorch JH, Hammerman PS. <article-title>Genomic analysis of metastatic cutaneous squamous cell carcinoma</article-title>. <source>Clin Cancer Res</source><year>2015</year>; <volume>21</volume>: <fpage>1447</fpage>–1456.<pub-id pub-id-type="pmid">25589618</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-14-1773</pub-id><pub-id pub-id-type="pmcid">PMC4359951</pub-id></mixed-citation>
        </ref>
        <ref id="bib17">
          <mixed-citation publication-type="journal">Network TCGA. <article-title>Comprehensive genomic characterization of head and neck squamous cell carcinomas</article-title>. <source>Nature</source><year>2015</year>; <volume>517</volume>: <fpage>576</fpage>–582.<pub-id pub-id-type="pmid">25631445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature14129</pub-id><pub-id pub-id-type="pmcid">PMC4311405</pub-id></mixed-citation>
        </ref>
        <ref id="bib18">
          <mixed-citation publication-type="journal">Jung S-H, Choi YJ, Kim MS, Baek I-P, Lee SH, Lee AW et al. <article-title>Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix</article-title>. <source>Oncotarget</source><year>2015</year>; <volume>6</volume>: <fpage>4385</fpage>–4393.<pub-id pub-id-type="pmid">25738363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.2981</pub-id><pub-id pub-id-type="pmcid">PMC4414197</pub-id></mixed-citation>
        </ref>
        <ref id="bib19">
          <mixed-citation publication-type="journal">Feber A, Worth DC, Chakravarthy A, de Winter P, Shah K, Arya M et al. <article-title>CSN1 somatic mutations in penile squamous cell carcinoma</article-title>. <source>Cancer Res</source><year>2016</year>; <volume>76</volume>: <fpage>4720</fpage>–4727.<pub-id pub-id-type="pmid">27325650</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-15-3134</pub-id><pub-id pub-id-type="pmcid">PMC5302160</pub-id></mixed-citation>
        </ref>
        <ref id="bib20">
          <mixed-citation publication-type="journal">Kim T-M, Jung S-H, Kim MS, Baek I-P, Park S-W, Lee SH et al. <article-title>The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers</article-title>. <source>J Pathol</source><year>2014</year>; <volume>234</volume>: <fpage>365</fpage>–374.<pub-id pub-id-type="pmid">25042771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.4401</pub-id></mixed-citation>
        </ref>
        <ref id="bib21">
          <mixed-citation publication-type="journal">Li H, Durbin R. <article-title>Fast and accurate short read alignment with Burrows–Wheeler transform</article-title>. <source>Bioinformatics</source><year>2009</year>; <volume>25</volume>: <fpage>1754</fpage>–1760.<pub-id pub-id-type="pmid">19451168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btp324</pub-id><pub-id pub-id-type="pmcid">PMC2705234</pub-id></mixed-citation>
        </ref>
        <ref id="bib22">
          <mixed-citation publication-type="journal">DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al. <article-title>A framework for variation discovery and genotyping using next-generation DNA sequencing data</article-title>. <source>Nat Genet</source><year>2011</year>; <volume>43</volume>: <fpage>491</fpage>–498.<pub-id pub-id-type="pmid">21478889</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.806</pub-id><pub-id pub-id-type="pmcid">PMC3083463</pub-id></mixed-citation>
        </ref>
        <ref id="bib23">
          <mixed-citation publication-type="journal">Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N et al. <article-title>The Sequence Alignment/Map format and SAMtools</article-title>. <source>Bioinformatics</source><year>2009</year>; <volume>25</volume>: <fpage>2078</fpage>–2079.<pub-id pub-id-type="pmid">19505943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btp352</pub-id><pub-id pub-id-type="pmcid">PMC2723002</pub-id></mixed-citation>
        </ref>
        <ref id="bib24">
          <mixed-citation publication-type="journal">Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C et al. <article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>. <source>Nat Biotechnol</source><year>2013</year>; <volume>31</volume>: <fpage>213</fpage>–219.<pub-id pub-id-type="pmid">23396013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.2514</pub-id><pub-id pub-id-type="pmcid">PMC3833702</pub-id></mixed-citation>
        </ref>
        <ref id="bib25">
          <mixed-citation publication-type="journal">Wang K, Li M, Hakonarson H. <article-title>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data</article-title>. <source>Nucleic Acids Res</source><year>2010</year>; <volume>38</volume>: <fpage>e164</fpage>–e164.<pub-id pub-id-type="pmid">20601685</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkq603</pub-id><pub-id pub-id-type="pmcid">PMC2938201</pub-id></mixed-citation>
        </ref>
        <ref id="bib26">
          <mixed-citation publication-type="journal">Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. <article-title>A method and server for predicting damaging missense mutations</article-title>. <source>Nat Methods</source><year>2010</year>; <volume>7</volume>: <fpage>248</fpage>–249.<pub-id pub-id-type="pmid">20354512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmeth0410-248</pub-id><pub-id pub-id-type="pmcid">PMC2855889</pub-id></mixed-citation>
        </ref>
        <ref id="bib27">
          <mixed-citation publication-type="journal">Roberts SA, Sterling J, Thompson C, Harris S, Mav D, Shah R et al. <article-title>Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions</article-title>. <source>Mol Cell</source><year>2012</year>; <volume>46</volume>: <fpage>424</fpage>–435.<pub-id pub-id-type="pmid">22607975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molcel.2012.03.030</pub-id><pub-id pub-id-type="pmcid">PMC3361558</pub-id></mixed-citation>
        </ref>
        <ref id="bib28">
          <mixed-citation publication-type="journal">Gehring JS, Fischer B, Lawrence M, Huber W. <article-title>SomaticSignatures: inferring mutational signatures from single-nucleotide variants</article-title>. <source>Bioinformatics</source><year>2015</year>; <volume>31</volume>: <fpage>3673</fpage>–3675.<pub-id pub-id-type="pmid">26163694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/btv408</pub-id><pub-id pub-id-type="pmcid">PMC4817139</pub-id></mixed-citation>
        </ref>
        <ref id="bib29">
          <mixed-citation publication-type="journal">Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H et al. <article-title>COSMIC: exploring the world’s knowledge of somatic mutations in human cancer</article-title>. <source>Nucleic Acids Res</source><year>2015</year>; <volume>43</volume>: <fpage>D805</fpage>–D811.<pub-id pub-id-type="pmid">25355519</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gku1075</pub-id><pub-id pub-id-type="pmcid">PMC4383913</pub-id></mixed-citation>
        </ref>
        <ref id="bib30">
          <mixed-citation publication-type="journal">Network TCGA. <article-title>Comprehensive molecular portraits of human breast tumours</article-title>. <source>Nature</source><year>2012</year>; <volume>490</volume>: <fpage>61</fpage>–70.<pub-id pub-id-type="pmid">23000897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature11412</pub-id><pub-id pub-id-type="pmcid">PMC3465532</pub-id></mixed-citation>
        </ref>
        <ref id="bib31">
          <mixed-citation publication-type="journal">Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM et al. <article-title>Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers</article-title>. <source>Cancer Discov</source><year>2013</year>; <volume>3</volume>: <fpage>770</fpage>–781.<pub-id pub-id-type="pmid">23619168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-12-0537</pub-id><pub-id pub-id-type="pmcid">PMC3858325</pub-id></mixed-citation>
        </ref>
        <ref id="bib32">
          <mixed-citation publication-type="journal">Hayes TF, Benaich N, Goldie SJ, Sipilä K, Ames-Draycott A, Cai W et al. <article-title>Integrative genomic and functional analysis of human oral squamous cell carcinoma cell lines reveals synergistic effects of FAT1 and CASP8 inactivation</article-title>. <source>Cancer Lett</source><year>2016</year>; <volume>383</volume>: <fpage>106</fpage>–114.<pub-id pub-id-type="pmid">27693639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2016.09.014</pub-id><pub-id pub-id-type="pmcid">PMC5090049</pub-id></mixed-citation>
        </ref>
        <ref id="bib33">
          <mixed-citation publication-type="journal">India Project Team of the International Cancer Genome Consortium. <article-title>Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups</article-title>. <source>Nat Commun</source><year>2013</year>; <volume>4</volume>: <fpage>2873</fpage>.<pub-id pub-id-type="pmid">24292195</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms3873</pub-id><pub-id pub-id-type="pmcid">PMC3863896</pub-id></mixed-citation>
        </ref>
        <ref id="bib34">
          <mixed-citation publication-type="journal">Jung S-H, Shin S, Kim MS, Baek I-P, Lee JY, Lee SH et al. <article-title>Genetic progression of high grade prostatic intraepithelial neoplasia to prostate cancer</article-title>. <source>Eur Urol</source><year>2016</year>; <volume>69</volume>: <fpage>823</fpage>–830.<pub-id pub-id-type="pmid">26542946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2015.10.031</pub-id></mixed-citation>
        </ref>
        <ref id="bib35">
          <mixed-citation publication-type="journal">Favero F, Joshi T, Marquard AM, Birkbak NJ, Krzystanek M, Li Q et al. <article-title>Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data</article-title>. <source>Ann Oncol</source><year>2015</year>; <volume>26</volume>: <fpage>64</fpage>–70.<pub-id pub-id-type="pmid">25319062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdu479</pub-id><pub-id pub-id-type="pmcid">PMC4269342</pub-id></mixed-citation>
        </ref>
        <ref id="bib36">
          <mixed-citation publication-type="journal">Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R et al. <article-title>A census of human cancer genes</article-title>. <source>Nat Rev Cancer</source><year>2004</year>; <volume>4</volume>: <fpage>177</fpage>–183.<pub-id pub-id-type="pmid">14993899</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc1299</pub-id><pub-id pub-id-type="pmcid">PMC2665285</pub-id></mixed-citation>
        </ref>
        <ref id="bib37">
          <mixed-citation publication-type="journal">Dizdaroglu M. <article-title>Oxidatively induced DNA damage: mechanisms, repair and disease</article-title>. <source>Cancer Lett</source><year>2012</year>; <volume>327</volume>: <fpage>26</fpage>–47.<pub-id pub-id-type="pmid">22293091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.canlet.2012.01.016</pub-id></mixed-citation>
        </ref>
        <ref id="bib38">
          <mixed-citation publication-type="journal">Thomas LK, Bermejo JL, Vinokurova S, Jensen K, Bierkens M, Steenbergen R et al. <article-title>Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract – a systematic review and meta-analysis</article-title>. <source>Eur J Cancer</source><year>2014</year>; <volume>50</volume>: <fpage>85</fpage>–98.<pub-id pub-id-type="pmid">24054023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2013.08.022</pub-id></mixed-citation>
        </ref>
        <ref id="bib39">
          <mixed-citation publication-type="journal">Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K et al. <article-title>Mutational processes molding the genomes of 21 breast cancers</article-title>. <source>Cell</source><year>2012</year>; <volume>149</volume>: <fpage>979</fpage>–993.<pub-id pub-id-type="pmid">22608084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2012.04.024</pub-id><pub-id pub-id-type="pmcid">PMC3414841</pub-id></mixed-citation>
        </ref>
        <ref id="bib40">
          <mixed-citation publication-type="journal">Tuna M, Knuutila S, Mills GB. <article-title>Uniparental disomy in cancer</article-title>. <source>Trends Mol Med</source><year>2009</year>; <volume>15</volume>: <fpage>120</fpage>–128.<pub-id pub-id-type="pmid">19246245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2009.01.005</pub-id></mixed-citation>
        </ref>
        <ref id="bib41">
          <mixed-citation publication-type="journal">Dunbar AJ, Gondek LP, O’Keefe CL, Makishima H, Rataul MS, Szpurka H et al. <article-title>250K SNP array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies</article-title>. <source>Cancer Res</source><year>2008</year>; <volume>68</volume>: <fpage>10349</fpage>–10357.<pub-id pub-id-type="pmid">19074904</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-08-2754</pub-id><pub-id pub-id-type="pmcid">PMC2668538</pub-id></mixed-citation>
        </ref>
        <ref id="bib42">
          <mixed-citation publication-type="journal">Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV et al. <article-title>Signatures of mutational processes in human cancer</article-title>. <source>Nature</source><year>2013</year>; <volume>500</volume>: <fpage>415</fpage>–421.<pub-id pub-id-type="pmid">23945592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12477</pub-id><pub-id pub-id-type="pmcid">PMC3776390</pub-id></mixed-citation>
        </ref>
        <ref id="bib43">
          <mixed-citation publication-type="journal">Pfeifer GP. <article-title>Mutagenesis at methylated CpG sequences</article-title>. <source>Curr Top Microbiol Immunol</source><year>2006</year>; <volume>301</volume>: <fpage>259</fpage>–281.<pub-id pub-id-type="pmid">16570852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/3-540-31390-7_10</pub-id></mixed-citation>
        </ref>
        <ref id="bib44">
          <mixed-citation publication-type="journal">Noia JMD, Neuberger MS. <article-title>Molecular mechanisms of antibody somatic hypermutation</article-title>. <source>Annu Rev Biochem</source><year>2007</year>; <volume>76</volume>: <fpage>1</fpage>–22.<pub-id pub-id-type="pmid">17328676</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.biochem.76.061705.090740</pub-id></mixed-citation>
        </ref>
        <ref id="bib45">
          <mixed-citation publication-type="journal">Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. <article-title>APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development</article-title>. <source>Cell Rep</source><year>2014</year>; <volume>7</volume>: <fpage>1833</fpage>–1841.<pub-id pub-id-type="pmid">24910434</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2014.05.012</pub-id></mixed-citation>
        </ref>
        <ref id="bib46">
          <mixed-citation publication-type="journal">Han S, Park J, Lee D-H. <article-title>Protein DHX38 is a novel inhibitor of protein phosphatase 4</article-title>. <source>Anim Cells Syst</source><year>2015</year>; <volume>19</volume>: <fpage>236</fpage>–244.</mixed-citation>
        </ref>
        <ref id="bib47">
          <mixed-citation publication-type="journal">Morris LGT, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, Turcan S et al. <article-title>Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation</article-title>. <source>Nat Genet</source><year>2013</year>; <volume>45</volume>: <fpage>253</fpage>–261.<pub-id pub-id-type="pmid">23354438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2538</pub-id><pub-id pub-id-type="pmcid">PMC3729040</pub-id></mixed-citation>
        </ref>
        <ref id="bib48">
          <mixed-citation publication-type="journal">Kim KT, Kim B-S, Kim JH. <article-title>Association between FAT1 mutation and overall survival in patients with human papillomavirus–negative head and neck squamous cell carcinoma</article-title>. <source>Head Neck</source><year>2016</year>; <volume>38</volume>: <fpage>E2021</fpage>–E2029.<pub-id pub-id-type="pmid">26876381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hed.24372</pub-id><pub-id pub-id-type="pmcid">PMC5067633</pub-id></mixed-citation>
        </ref>
        <ref id="bib49">
          <mixed-citation publication-type="journal">Yim E-K, Park J-S. <article-title>The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis</article-title>. <source>Cancer Res Treat Off J Korean Cancer Assoc</source><year>2005</year>; <volume>37</volume>: <fpage>319</fpage>–324.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4143/crt.2005.37.6.319</pub-id><pub-id pub-id-type="pmcid">PMC2785934</pub-id><pub-id pub-id-type="pmid">19956366</pub-id></mixed-citation>
        </ref>
        <ref id="bib50">
          <mixed-citation publication-type="journal">Tomaić V. <article-title>Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites</article-title>. <source>Cancers</source><year>2016</year>; <volume>8</volume>: <fpage>pii: E95</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers8100095</pub-id><pub-id pub-id-type="pmcid">PMC5082385</pub-id><pub-id pub-id-type="pmid">27775564</pub-id></mixed-citation>
        </ref>
      </ref-list>
      <sec sec-type="supplementary-material" id="sup1">
        <title>Supplementary Material</title>
        <supplementary-material content-type="local-data" id="xob1" position="float" orientation="portrait">
          <label>Supplementary Table 1</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emm2017265x1.pdf" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="xob2" position="float" orientation="portrait">
          <label>Supplementary Table 2</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emm2017265x2.pdf" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="xob3" position="float" orientation="portrait">
          <label>Supplementary Table 3</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emm2017265x3.pdf" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="xob4" position="float" orientation="portrait">
          <label>Supplementary Table 4</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emm2017265x4.pdf" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="xob5" position="float" orientation="portrait">
          <label>Supplementary Figures</label>
          <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="emm2017265x5.docx" position="float" orientation="portrait">
            <caption>
              <p>Click here for additional data file.</p>
            </caption>
          </media>
        </supplementary-material>
      </sec>
    </back>
    <floats-group>
      <fig id="fig1" position="float" orientation="portrait">
        <label>Figure 1</label>
        <caption>
          <p>Compositions of somatic mutations identified in vulvar cancer genomes. (<bold>a</bold>) Mutation frequency in vulvar cancer genomes compared with those in other squamous cell carcinomas (CESC, cervical squamous cell carcinoma; CSCC, skin cutaneous squamous cell carcinoma; ESCA, esophageal squamous cell carcinoma; HNSC, head and neck squamous cell carcinoma; LUSC, lung squamous cell carcinoma; OSCC, oral squamous cell carcinoma; Mb, megabase). The median mutation frequency value is indicated next to each bar. Numbers of cases for each squamous cell carcinoma are shown in parentheses. (<bold>b</bold>) Number of somatic mutations (upper plot) and type of base pair substitution (lower plot) of 15 vulvar SCC genomes (6 HPV (+) and 9 HPV (−)) are shown. A total of 2084 nonsilent and 924 silent mutations were identified in 15 vulvar SCC genomes.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="emm2017265f1.jpg"/>
      </fig>
      <fig id="fig2" position="float" orientation="portrait">
        <label>Figure 2</label>
        <caption>
          <p>Putative driver mutations identified in vulvar SCCs. (<bold>a</bold>) Cancer-related genes listed in the Cancer Gene Census (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/census">http://cancer.sanger.ac.uk/census</ext-link>) identified in this study are shown for each sample. Fractions of each mutation in the SCCs are shown in the left plot. (<bold>b</bold>) Schematic representation of FAT1 protein domains and predicted locations of the mutations detected in vulvar SCCs. Black dot, truncating mutation; Green dot, missense mutation.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="emm2017265f2.jpg"/>
      </fig>
      <fig id="fig3" position="float" orientation="portrait">
        <label>Figure 3</label>
        <caption>
          <p>Mutation signatures of vulvar cancers. (<bold>a</bold>) The contribution of each signature to the filtered somatic mutation burden for each SCC. HPV status is shown in black (HPV (+)) and gray (HPV (−)). (<bold>b</bold>) Mutations within a trinucleotide context split by each of the two signatures generated from the NMF algorithm. (<bold>c</bold>) Each plot shows similarities between the mutational signatures from vulvar cancers and 30 known mutation signatures from the COSMIC database. Bars with high similarities are colored in red (cosine similarity ⩾0.8).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="emm2017265f3.jpg"/>
      </fig>
      <fig id="fig4" position="float" orientation="portrait">
        <label>Figure 4</label>
        <caption>
          <p>Copy number alterations identified in HPV (+) vulvar SCCs. (<bold>a</bold>) Genome-wide frequency of copy number alterations in HPV (+) SCCs. Gain (positive axis, red). Loss (negative axis, blue). (<bold>b</bold>) Genome-wide frequency of copy number alterations in HPV (−) SCCs. (<bold>c</bold>) Focal amplification at the <italic toggle="yes">PIK3CA</italic> gene locus (3q26.32, red arrows) identified in four HPV (+) SCCs. Green arrows indicate <italic toggle="yes">PIK3CA</italic> missense mutations (p.E545K) in VSCC1 and 4.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="emm2017265f4.jpg"/>
      </fig>
      <fig id="fig5" position="float" orientation="portrait">
        <label>Figure 5</label>
        <caption>
          <p>Copy-neutral loss of heterozygosity (LOH) events identified in vulvar cancers. (<bold>a</bold>) Copy-neutral LOH events at cancer-related gene loci are highlighted with red square boxes. The upper bar represents the B allele frequency (0.0–0.5) and the lower bar represents the depth ratio (0.0–2.5). (<bold>b</bold>) List of copy-neutral LOH events identified in vulvar cancers. Four vulvar SCCs with copy-neutral LOH at cancer-related gene loci.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="emm2017265f5.jpg"/>
      </fig>
      <fig id="fig6" position="float" orientation="portrait">
        <label>Figure 6</label>
        <caption>
          <p>Kataegis identified in vulvar cancers. Regional hypermutation plots in two cancers. Upper panels of <bold>a</bold> and <bold>b</bold>: the left plot represents an individual sample in which each dot represents a single somatic mutation colored on a chromosomal basis. The right plot represents the same data colored by mutation type. Mutations are ordered consecutively on the <italic toggle="yes">x</italic> axis from the first mutation in the short arm of chromosome 1 to the last mutation in the long arm of chromosome X. Kataegis at chromosome 16 is highlighted by a red square box. Lower panels of <bold>a</bold> and <bold>b</bold>: kataegis loci are shown on chromosome 16.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="emm2017265f6.jpg"/>
      </fig>
      <table-wrap id="tbl1" position="float" orientation="portrait">
        <label>Table 1</label>
        <caption>
          <title>Clinicopathologic features of vulvar cancers</title>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="char" char="." span="1"/>
            <col align="char" char="." span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
          </colgroup>
          <thead valign="bottom">
            <tr>
              <th align="left" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Sample</italic>
              </th>
              <th align="center" valign="top" char="." charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Age (years)</italic>
              </th>
              <th align="center" valign="top" char="." charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Tumor size in diameter (cm)</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Diagnosis</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Extent of carcinoma</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">HPV infection (high- and low-risk types)</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Sample source</italic>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC1</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">60</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">3.5</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Microinvasion</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">+ (HPV16, −)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC2</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">74</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">invasion (7.0 mm)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">+ (HPV16, −)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Frozen</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC3</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">78</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Invasion (8.0 mm)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">+ (HPV58, −)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC4</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">61</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">0.5</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Microinvasion</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">+ (HPV16, −)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC5</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">66</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Invasion (6.0 mm)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">+ (HPV52, −)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC6</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">47</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">1.5</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Invasion (1.0 mm)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">+ (HPV16, −)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC7</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">70</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">2.5</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Invasion (7.0 mm)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">—</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC8</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">70</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">4</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Invasion (4.0 mm)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">—</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC9</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">45</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">1.3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC (VIN)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">No invasion</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">—</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC10</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">61</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">0.6</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Invasion (1.4 mm)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">—</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC11</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">62</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">2.4</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Invasion (1.0 mm)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">—</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC12</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">69</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">4</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Invasion (7.0 mm)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">—</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC13</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">79</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">4</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Invasion (1.0 mm)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">—</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC14</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">64</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">1.7</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva (VIN) SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">No invasion</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">—</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">VSCC15</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">83</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">1.2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Vulva SCC</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Invasion (4.0 mm)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">—</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">FFPE</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t1-fn1">
            <p>Abbreviations: FFPE, formalin-fixed paraffin-embedded; HPV, human papilloma virus; VIN, vulva intraepithelial neoplasm.</p>
          </fn>
          <fn id="t1-fn2">
            <p>HPV infection risk types are indicated in parentheses (high risk, low risk).</p>
          </fn>
          <fn id="t1-fn3">
            <p>High-risk HPVs are indicated by the numbers 16, 52, and 58.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="tbl2" position="float" orientation="portrait">
        <label>Table 2</label>
        <caption>
          <title>Summary of comparison data between HPV (+) and HPV (−) vulvar cancer genomes</title>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="char" char="." span="1"/>
          </colgroup>
          <thead valign="bottom">
            <tr>
              <th align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">HPV (+)</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">HPV (−)</italic>
              </th>
              <th align="center" valign="top" char="." charoff="50" colspan="1" rowspan="1">P<italic toggle="yes">-value</italic></th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Somatic mutation number</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">116.8/tumor</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">256.3/tumor</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">0.03</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Mutation allele frequency</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">0.23/variant</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">0.15/variant</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">&lt;0.001</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Nonsilent mutation number</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">84.8/tumor</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">175/tumor</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">0.03</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Mutation allele frequency (nonsilent)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">0.23/variant</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">0.16/variant</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">&lt;0.001</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Silent mutation number</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">32/tumor</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">81.3/tumor</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">0.03</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Mutation frequency (silent)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">0.23/variant</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">0.14/variant</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">&lt;0.001</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Putative driver mutation number</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2.8/tumor</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">10.6/tumor</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">0.0002</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Representative driver mutation</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1"><italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">FBXW7</italic>, <italic toggle="yes">BRCA2</italic></td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1"><italic toggle="yes">FBXW7</italic>, <italic toggle="yes">BRCA2</italic>, <italic toggle="yes">TP53</italic>, <italic toggle="yes">HRAS</italic>, <italic toggle="yes">FAT1</italic>, <italic toggle="yes">APC</italic>, <italic toggle="yes">CDKN2A</italic></td>
              <td align="center" valign="top" char="." charoff="50" colspan="1" rowspan="1">—</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">No. of CNAs</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">238 (median: 22.0)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">352 (median: 10.m)</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">0.53</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Length of CNAs (Mb)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2430.0 (median: 193.1)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2495.4 (median: 96.4)</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1">0.75</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Most recurrent copy gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3q</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">7p, 8q</td>
              <td align="center" valign="top" char="." charoff="50" colspan="1" rowspan="1">—</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Most recurrent copy loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">11q</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2q</td>
              <td align="center" valign="top" char="." charoff="50" colspan="1" rowspan="1">—</td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">Kataegis</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Positive (<italic toggle="yes">n</italic>=2)</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">Negative (<italic toggle="yes">n</italic>=0)</td>
              <td align="char" valign="top" char="." charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t2-fn1">
            <p>Abbreviation: CNAs, copy number alterations.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap id="tbl3" position="float" orientation="portrait">
        <label>Table 3</label>
        <caption>
          <title>Recurrently altered regions in vulvar SCCs by HPV status</title>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup span="1">
            <col align="left" span="1"/>
            <col align="left" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="left" span="1"/>
          </colgroup>
          <thead valign="bottom">
            <tr>
              <th align="left" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">HPV status</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Event</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Chr</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Map position</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Size</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Cytoband</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Freq</italic>
              </th>
              <th align="center" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">Cancer-related genes</italic>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">HPV (<bold>+)</bold></td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">1</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">144 214 303–144 596 037</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">381734</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q21.1</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">118 644 873–159 947 520</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">41302647</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q13.32–q25.33</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">67%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"><italic toggle="yes">GATA2</italic>, <italic toggle="yes">RPN1</italic>, <italic toggle="yes">CNBP</italic>, <italic toggle="yes">FOXL2</italic>, <italic toggle="yes">ATR</italic>, <italic toggle="yes">WWTR1</italic>, <italic toggle="yes">GMPS</italic>, <italic toggle="yes">MLF1</italic></td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">160 282 987–198 022 430</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">37739443</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q25.33–q29</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">83%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"><italic toggle="yes">MECOM</italic>, <italic toggle="yes">TBL1XR1</italic>, <italic toggle="yes">PIK3CA</italic>, <italic toggle="yes">SOX2</italic>, <italic toggle="yes">MAP3K13</italic>, <italic toggle="yes">ETV5</italic>, <italic toggle="yes">EIF4A2</italic>, <italic toggle="yes">BCL6</italic>, <italic toggle="yes">LPP</italic>, <italic toggle="yes">TP63</italic>, <italic toggle="yes">TFRC</italic></td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">5</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">140 372–23 884 365</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">23743993</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p15.33–p14.2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"><italic toggle="yes">SDHA</italic>, <italic toggle="yes">TERT</italic></td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">5</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">31 552 901–34 688 160</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3135259</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p13.3–p13.2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">11</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">96 124 552–99 487 602</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3363050</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q21–q22.1</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">11</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">101 762 008–103 349 792</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">1587784</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q22.1–q22.3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">BIRC3</italic>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">13</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">100 336 156–101 714 451</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">1378295</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q32.3–q33.1</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">18</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2 796 420–17 200 000</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">14403580</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p11.32–q11.1</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">67%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">18</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">18 517 121–34 840 647</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">16323526</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q11.1–q12.2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"><italic toggle="yes">ZNF521</italic>, <italic toggle="yes">SS18</italic></td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">18</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43 422 074–45 567 137</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2145063</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q12.3–q21.1</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">SMAD2</italic>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">18</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">46 645 092–47 957 549</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">1312457</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q21.1</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">18</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">51 690 882–67 872 291</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">16181409</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q21.2–q22.2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"><italic toggle="yes">MALT1</italic>, <italic toggle="yes">BCL2</italic>, <italic toggle="yes">KDSR</italic></td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">20</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3 847 585–21 402 481</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">17554896</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p13–p11.22</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">20</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">47 465 498–58 744 996</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">11279498</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q13.13–q13.33</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"><italic toggle="yes">NFATC2</italic>, <italic toggle="yes">SALL4</italic>, <italic toggle="yes">GNAS</italic></td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">HPV (−)</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3 698 900–3 698 947</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">47</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p25.3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">192 746 283–196 581 520</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3835237</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q32.3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">57%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">202 625 760–203 620 248</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">994488</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q33.1–q33.2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">49 949 001–50 191 322</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">242321</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p21.31</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">50 683 675–50 816 138</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">132463</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p21.2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">51 497 186–51 696 851</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">199665</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p21.2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">81 792 616–87 027 712</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">5235096</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p12.2–p12.1</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">4</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">187 630 720–189 660 328</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2029608</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q35.2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">
                <italic toggle="yes">FAT1</italic>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">7</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">766 289–2 771 308</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2005019</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p22.3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">7</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">5 256 327–5 692 158</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">435831</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p22.1</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">7</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">16 131 179–48 567 889</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">32436710</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p21.2–p12.3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">57%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"><italic toggle="yes">HNRNPA2B1</italic>, <italic toggle="yes">HOXA9</italic>, <italic toggle="yes">HOXA11</italic>, <italic toggle="yes">HOXA13</italic>, <italic toggle="yes">JAZF1</italic>, <italic toggle="yes">SFRP4</italic></td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">8</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">141 542 615–142 489 103</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">946488</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q24.3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">57%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">8</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">145 918 761–146 364 022</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">445261</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q24.3</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">10</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">99 426 796–99 473 736</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">46940</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q24.2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Gain</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">14</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">22 386 737–23 012 133</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">625396</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q11.2</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">21</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">5305–13 200 000</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">13194695</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p13–q11.1</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">X</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">0–2 616 478</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">2616478</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">p22.33</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"><italic toggle="yes">CRLF2</italic>, <italic toggle="yes">P2RY8</italic></td>
            </tr>
            <tr>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1">CN Loss</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">X</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">61 686 735–62 569 812</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">883077</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">q11.1</td>
              <td align="center" valign="top" charoff="50" colspan="1" rowspan="1">43%</td>
              <td align="left" valign="top" charoff="50" colspan="1" rowspan="1"> </td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t3-fn1">
            <p>Abbreviations: CN gain, copy number gain; CN loss, copy number loss; Freq, frequency.</p>
          </fn>
          <fn id="t3-fn2">
            <p>CNAs occurring in more than 40% of samples were defined as recurrently altered regions.</p>
          </fn>
          <fn id="t3-fn3">
            <p>Cancer-related genes were extracted from the Cancer Gene Census (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://cancer.sanger.ac.uk/census">http://cancer.sanger.ac.uk/census</ext-link>) and genes previously reported in vulvar SCCs.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib13">13</xref>, <xref ref-type="bibr" rid="bib14">14</xref>, <xref ref-type="bibr" rid="bib15">15</xref></sup></p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </floats-group>
  </article>
</pmc-articleset>
